(Metyrapone + oxazepam) is under clinical development by Embera NeuroTherapeutics and currently in Phase II for Substance (Drug) Abuse. According to GlobalData, Phase II drugs for Substance (Drug) ...

Agents that directly lower ACTH secretion by a pituitary adenoma represent an attractive option for the treatment of Cushing's disease, as these drugs directly target the pathogenesis of disease ...

Expert Rev Endocrinol Metab. 2013;8(2):183-193. To date, there are no clinical studies evaluating the combination of mifepristone with other available agents. As treatment with mifepristone ...

These could both be investigated in the context of therapeutics like metyrapone, a GC inhibitor, which could alleviate these effects while maintaining adequate anti-tumor effects, while also allowing ...

The powerful sedative xylazine has been detected in cannabis vapes. Credit: PavelKant/Shutterstock. The UK government has taken a significant step towards banning xylazine, commonly referred to as the ...